Susquehanna International Group, LLP Adc Therapeutics Sa Transaction History
Susquehanna International Group, LLP
- $823 Billion
- Q3 2025
A detailed history of Susquehanna International Group, LLP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Susquehanna International Group, LLP holds 48,800 shares of ADCT stock, worth $193,248. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,800
Previous 115,232
57.65%
Holding current value
$193,248
Previous $308,000
36.69%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding ADCT
# of Institutions
108Shares Held
67.3MCall Options Held
39.8KPut Options Held
68.4K-
Redmile Group, LLC San Francisco, CA15.7MShares$62 Million6.9% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct8.14MShares$32.2 Million0.06% of portfolio
-
Prosight Management, LP Dallas, TX7.47MShares$29.6 Million7.9% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$23.4 Million0.81% of portfolio
-
Morgan Stanley New York, NY3.67MShares$14.5 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $307M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...